New combo therapy shows promise for tough lymphoma cases
NCT ID NCT04539444
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if the combo could shrink tumors or slow disease progression. Results are not yet widely available, but the study aims to offer a new option for patients who have run out of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/22 CAR-T cells and tislelizumab (PD-1 inhibitor)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has not responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 18 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cells engineered to fight lymphoma enter human testing
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma
- New study aims to crack the code of treatment resistance in lymphoma
- New injection shows promise for Hard-to-Treat cancers
- Triple-Target CAR T-Cells offer new hope for tough blood cancers